Month: September 2023

NEW YORK, Sept. 6, 2023 /PRNewswire/ — The needle-free injection systems market size is expected to grow by USD 15.37 billion from 2022 to 2027. In addition momentum of the market will progress at a CAGR of 15.06% during the forecast period, according to Technavio Research. North America…

Latest funding round is one of the largest U.S. cleantech equity private placements of 2023 to date Highlights Decarbonization Partners, Temasek, and Qatar Investment Authority (QIA) are leading the Series D funding round. Ascend Elements will use the proceeds to build the United States’…

MARIPOSA-2 is the first Phase 3 study to show statistically significant and clinically meaningful improvement in progression-free survival (PFS) in the post-osimertinib setting MARIPOSA-2 is the second RYBREVANT® Phase 3 study to show the potential to improve outcomes in patients with…

LA JOLLA, Calif., Sept. 6, 2023 /PRNewswire/ — CalciMedica Inc. (“CalciMedica”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic…

Program Uses “Patient-Actors” and Self-Testing to Diagnose Neurological Ailments NEW YORK, Sept. 6, 2023 /PRNewswire/ — A new physician-training system in telehealth simulates key parts of traditional, in-person neurological exams that use little reflex hammers, pinpricks, and…

The long-term partnership aims to emphasize the empowerment of natural beauty, with Alma committed to delivering safe, effective, and evidence-based solutions. The actress and entrepreneur will be featured in a brand-new campaign themed “Beyond the Trend,” highlighting reliable aesthetic…

Report finds QSR consumers are more than 2x as likely to have the XUMO, Pluto TV, Crackle, and Disney+ CTV streaming apps compared to the General Market TORONTO, Sept. 6, 2023 /PRNewswire/ — Sabio Holdings Inc. (TSXV: SBIO; OTCQX: SABOF) (the “Company” or “Sabio”), a leading provider of…

NEW HAVEN, Conn., Sept. 6, 2023 /PRNewswire/ — Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for difficult to treat patients with chronic cough in idiopathic pulmonary fibrosis…

–Transaction Will Strengthen Persist’s Position as an Emerging Player in the Southern Alberta Mannville Formation– CALGARY, AB and HOUSTON, Sept. 6 , 2023 /PRNewswire/ — Persist Oil and Gas, Inc. (“Persist”) and Dienerian Resources Inc. (“Dienerian”) announced today that they have…